CAMBRIDGE, Mass., Sept. 23 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced that John A.
McCarthy, Jr. has joined the Xanthus management team as Senior Vice President
and Chief Financial Officer.
"John brings to Xanthus tremendous leadership skills in our industry and
the financial, operations and investor relations experience needed to take our
company to the next level," stated Richard T. Dean, Ph.D., President and CEO
of Xanthus. "We are pleased to continue to attract high caliber talent such
as John. The strength of our team is enabling us to execute on our business
strategy while making important contributions to the field of oncology and
personalized dosing of medications."
John McCarthy joins Xanthus from Synta Pharmaceuticals Corp. where he was
Senior Vice President and Chief Financial Officer. Prior to Synta, Mr.
McCarthy was at Exact Sciences Corporation where he served as Executive Vice
President and Chief Financial Officer. Mr. McCarthy joined Exact Sciences in
2000 as a privately-held company and shortly thereafter led its successful
initial public offering and subsequent public financing. Additionally, Mr.
McCarthy was instrumental in developing the strategic corporate partnerships
and operational infrastructure necessary for the company's national launch of
its first commercial product in 2003. Prior to Exact Sciences, Mr. McCarthy's
healthcare experience included serving as President of InfoMedtrics
Corporation (privately-held), President of the Managed Care Division of
Concentra Managed Care, Inc. (publicly-traded), and SVP and CFO of MedChem
Products, Inc. (publicly-traded). Additionally, Mr. McCarthy's prior
experience included serving as an investment banking associate with Morgan
Stanley. Mr. McCarthy is a graduate of Lehigh University and Harvard Business
School. Mr. McCarthy serves on the Board of Directors of Signet Laboratories,
Inc.
About Xanthus
Xanthus is an oncology drug development company. Xanthus' small molecule
candidates are Xanafide(TM), Symadex(TM) and Clomet(TM) which are advancing in
clinical and preclinical development for multiple cancer indications. Each of
these product candidates was in-licensed based on significant clinical and/or
preclinical data supporting safety and activity. Xanthus also has proprietary
technology to individualize patient dosing, which it believes may help improve
the performance of certain drugs in development, and facilitate the life cycle
management of certain marketed products, without limiting patient populations
or markets.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson,
MacDougall Biomedical Communications, Inc. - kwatson@macbiocom.com
or (508) 647-0209
Richard T. Dean, Ph.D., Chief Executive Officer,
Xanthus Life Sciences - (617) 225-0522
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
Richard T. Dean, Ph.D. of Chief Executive Officer of Xanthus Life
Sciences, Inc., +1-617-225-0522
|
